From None.: 2024-10-30 13:58:00

AbbVie (NYSE:ABBV) raised its full-year earnings forecast after Q3 net revenue of $14.46 billion, a 3.8% increase from last year, surpassed analyst expectations. Adjusted earnings per share hit $3.00, beating estimates. Skyrizi sales jumped 50.8% to $3.21 billion, offsetting a 37.2% drop in Humira revenue. Shares rose over 5%. The company now expects adjusted earnings per share of $10.90 to $10.94 for the year and announced a 5.8% dividend increase.



Read more at None.:: AbbVie Raises Full-Year Forecast, Stock Gains 5%